JCR Pharmaceuticals (4552) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key point of this quarter’s results is that, despite securing revenue growth, the operating loss expanded significantly from the previous year due to a sharp increase in SG&A expenses. Revenue was ¥97.0B (+13.2% YoY), Operating Income was ¥-21.0B (¥-6.1B in the previous year), Ordinary Income was ¥-20.8B (¥-7.5B in the previous year), and consolidated Net Income was ¥-19.2B (¥-5.7B in the previous year). While the earnings structure improved, with the gross margin improving to 76.8% (up +4.3pt from 72.5% in the previous year), SG&A expenses surged to ¥95.5B (¥68.2B in the previous year, +40.1%), exceeding gross profit of ¥74.5B. This was the direct cause of the wider loss.

Factors Affecting Financial Results

【Revenue】Revenue was ¥97.0B, representing a +13.2% increase YoY. As the Company operates in a single segment (Pharmaceuticals Business), no breakdown by business is disclosed. However, gross profit was ¥74.5B and the gross margin improved to 76.8% from 72.5% in the previous year, an improvement of +4.3pt. In addition to revenue growth, improvements in product mix and cost efficiency appear to have contributed.

【Profit and Loss】The primary cause of the deterioration in Operating Income to ¥-21.0B (¥-6.1B in the previous year) was the sharp increase in SG&A expenses to ¥95.5B (¥68.2B in the previous year, +40.1%), exceeding gross profit (¥74.5B). Non-operating income and expenses resulted in income of ¥2.6B, including foreign exchange gains of ¥0.6B. However, the increased burden of interest expense of ¥1.6B (nearly double the ¥0.8B in the previous year) resulted in Ordinary Income of ¥-20.8B (¥-7.5B in the previous year). Extraordinary income and expenses were zero in the current period (slightly negative in the previous year due to losses on disposal of fixed assets and other items), and Profit Before Tax was ¥-20.8B, approximately the same level as Ordinary Income. As corporate income taxes and other taxes of ¥-1.7B were recorded, reflecting a tax refund, consolidated Net Income was ¥-19.2B (¥-5.7B in the previous year), while Net Income attributable to owners of the parent was ¥-19.1B (¥-5.5B in the previous year). Despite revenue growth, this was a case of lower earnings due to higher fixed costs, with losses widening at the Operating Income, Ordinary Income, and Net Income levels.

Key Financial Indicators

【Profitability】The Operating Margin deteriorated by -14.6pt to -21.7% (-7.1% in the previous year), while the Net Profit Margin on a consolidated basis deteriorated by -13.1pt to -19.8% (-6.7% in the previous year). Although the gross margin improved by +4.3pt to 76.8% (72.5% in the previous year), the SG&A ratio rose sharply to 98.5% (79.6% in the previous year), becoming the primary cause of the deterioration in profitability. 【Cash Quality】Comprehensive Income was ¥-25.1B, representing a difference of ¥-6.0B from Net Income attributable to owners of the parent of ¥-19.1B. The primary cause was a ¥-6.1B deterioration in valuation differences on investment securities; in addition to business operating results, market factors further reduced Comprehensive Income. 【Investment Efficiency】ROE was -4.4% (-1.2% in the previous year). Against total assets of ¥1,064.0B, revenue was ¥97.0B, resulting in total asset turnover of only 0.091x, indicating a low level of asset efficiency. 【Financial Soundness】The Equity Ratio declined by -2.3pt to 40.6% (42.9% in the previous year). Interest-bearing debt (short-term borrowings of ¥420.9B + long-term borrowings of ¥118.5B) was ¥539.4B, approximately unchanged from the previous year, but stood at approximately 1.25x equity. The current ratio was 108.9% and the quick ratio was 104.4%, maintaining a minimum safety margin.

Cash Flow Analysis

As no figures are available based on the classification disclosed in the statement of cash flows, cash trends are analyzed based on changes in balance sheet balances. Cash and deposits were ¥96.6B, down ¥43.5B (-31.0%) from ¥140.1B in the previous year, indicating that cash on hand is declining while operating losses continue. Accounts receivable and notes receivable increased to ¥156.9B (¥141.6B in the previous year, +10.8%), with receivables growing slightly ahead of revenue. Accounts payable also increased to ¥6.7B (¥5.2B in the previous year, +28.3%). Construction in progress, included in property, plant and equipment, remained high at ¥192.6B, suggesting that capital expenditures continue to absorb funds. Borrowings totaled ¥539.4B, comprising short-term borrowings of ¥420.9B and long-term borrowings of ¥118.5B, remaining approximately unchanged from the previous year. This suggests that the decline in cash on hand is being partially offset through continued borrowing.

Quality of Earnings

Ordinary Income was ¥-20.8B, while extraordinary income and expenses were zero in the current period (slightly negative in the previous year due to losses on disposal of fixed assets and other items). Accordingly, there was virtually no difference between Profit Before Tax (¥-20.8B) and Ordinary Income. The deterioration in earnings was therefore not attributable to extraordinary factors, but was primarily driven by recurring factors associated with the expansion of the operating loss in the core business. Of the ¥2.6B in non-operating income, the ¥0.6B foreign exchange gain includes an element related to market fluctuations, whereas the ¥1.6B in interest expense is a recurring cost linked to the balance of interest-bearing debt. Both items should be considered separately from the profit and loss structure of the core business. Comprehensive Income was ¥-25.1B, representing a difference of ¥-6.0B from Net Income attributable to owners of the parent of ¥-19.1B. The primary cause was a ¥-6.1B deterioration in valuation differences on securities resulting from the fair-value measurement of investment securities, with market factors separate from business operating results further reducing Comprehensive Income.

Earnings Forecasts and Guidance

The full-year forecast is revenue of ¥457.0B (+13.3% YoY), Operating Income of ¥11.0B (+98.2%), and Ordinary Income of ¥5.0B (-57.1%). Q1 revenue of ¥97.0B represents progress of 21.2% against the full-year forecast. Meanwhile, Q1 Operating Income and Ordinary Income were losses of ¥-21.0B and ¥-20.8B, respectively, representing substantial delays in progress toward the plan to achieve full-year profitability. The Company has not revised its earnings forecast or dividend forecast and has maintained its plan based on an improvement in earnings in the second half of the fiscal year.

Shareholder Returns

The annual dividend forecast is ¥10.00 (unchanged from the previous fiscal year), with no revision to the dividend forecast as of the end of this quarter. Compared with the full-year forecast EPS of ¥1.64, the Payout Ratio is approximately 610%, meaning that the planned total dividend amount substantially exceeds Net Income. As an operating loss has occurred in Q1, the dividend may depend on an allocation from retained earnings of ¥281.0B (down ¥31.3B YoY, -10.0%). There is no disclosure regarding the acquisition of treasury shares.

Risk Factors

1. Risk of deteriorating profitability due to fixed costs preceding revenue growth: SG&A expenses were ¥95.5B (98.5% of revenue), exceeding gross profit of ¥74.5B, and the Operating Margin deteriorated to -21.7% (-7.1% in the previous year). If elevated fixed costs continue, the loss-making structure may become prolonged.

2. Liquidity and refinancing risk: Short-term borrowings account for ¥420.9B of interest-bearing debt of ¥539.4B, while cash and deposits were ¥96.6B, representing only 0.23x the amount of short-term borrowings. As Operating Income was negative, the interest coverage ratio (Operating Income/interest expense) was also -13.4x, indicating that interest payments cannot be covered by core business earnings.

3. Risk of delays in the commencement of operations of capital expenditures: Construction in progress was ¥192.6B, accounting for 49.4% of property, plant and equipment. Delays in the commencement of operations or uncertainty regarding investment recovery could affect future depreciation expenses and asset efficiency.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

In terms of profitability, both the Operating Margin and Net Profit Margin were significantly below the industry median, placing the Company in the lower tier of the industry.

Growth and Capital Efficiency

The Revenue Growth Rate exceeded the industry median, indicating a relatively high level within the industry in terms of top-line growth.

※Source: Compiled by the Company

Key Points from the Financial Results

1. Despite revenue growth and an improvement in the gross margin (+4.3pt), SG&A expenses increased +40.1% YoY and exceeded gross profit. This was the direct cause of the deterioration in operating results, with the change in the cost structure being the most significant feature of the current period’s results.

2. Against the full-year earnings forecast of Operating Income of ¥11.0B, Q1 recorded a loss of ¥-21.0B, indicating a plan with a high degree of dependence on the second half of the fiscal year in terms of progress. No revision to the earnings forecast has been made.

3. The dividend forecast of ¥10.00 remains unchanged, but the planned Payout Ratio against full-year forecast EPS of ¥1.64 is approximately 610%. The fact that this represents a level premised on an allocation from retained earnings is a notable point that can be identified from the financial results data.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥265–¥280 at Cost of Equity ±1%; ¥270–¥274 at ω±0.1.

Notes:

• Net Income is significantly compressed relative to Operating Income due to tax burdens, acquisition-related expenses, minority interests, and other factors (Net Income ÷ Operating Income 18%). This figure reflects that compression at face value; if the factors are temporary, the underlying earnings power may be higher.
• As forecast ROE is below the Cost of Equity, the theoretical value is below Book Value Per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest benchmark month: 2026-06 / This figure is not a forecast or guarantee of the future share price.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was weak: revenue growth of 13.2% year on year did not offset a sharp increase in selling, general and administrative expenses, resulting in a materially wider loss. Revenue increased to ¥9.70bn from ¥8.57bn. Gross profit rose to ¥7.45bn from ¥6.21bn, and gross margin expanded by approximately 430 basis points to 76.8%. The gross-margin improvement indicates favorable product mix, pricing, or production-cost absorption at the gross-profit level. However, SG&A increased 40.1% year on year to ¥9.55bn, substantially outpacing revenue growth. SG&A consumed 98.5% of revenue, compared with 79.6% in the prior-year quarter. Consequently, operating loss widened to ¥2.10bn from ¥0.61bn. Operating margin deteriorated by approximately 1,460 basis points to negative 21.7%. Ordinary loss widened to ¥2.08bn, while net loss attributable to owners widened to ¥1.91bn from ¥0.55bn. Net margin declined by approximately 1,330 basis points to negative 19.7%. Non-operating income of ¥0.26bn, including ¥0.06bn of foreign-exchange gains, was insufficient to mitigate the operating loss, while interest expense doubled to ¥0.16bn. Annualized ROE was negative 17.5%, reflecting both the loss and the company's leveraged capital structure. The balance sheet remains pressured by ¥42.09bn of short-term borrowings, equivalent to 78.0% of interest-bearing debt, against ¥9.66bn of cash and deposits. Management maintained its FY2027 forecast of ¥45.70bn in revenue, ¥1.10bn in operating profit, and ¥0.20bn in profit attributable to owners, but Q1 results imply an exceptionally back-end-loaded recovery requirement. The investment focus is therefore on whether gross-margin gains can be retained while SG&A and development-related spending are brought into line with revenue growth, and whether short-term funding can be refinanced smoothly.

Profitability Analysis

Annualized DuPont ROE was negative 17.5%, comprising a negative 19.7% net profit margin, annualized asset turnover of 0.365x, and financial leverage of 2.44x. The principal driver of the negative return is the net-profit margin rather than asset turnover or leverage. Gross margin improved to 76.8% from approximately 72.5% in the prior-year quarter, demonstrating that the revenue increase was profitable at the gross-profit level. The deterioration instead occurred below gross profit: SG&A rose by ¥2.74bn, or 40.1% year on year, versus a ¥1.13bn, or 13.2%, increase in revenue. This created negative operating leverage, with operating loss expanding by ¥1.50bn. EBIT margin was negative 21.7%, a material efficiency concern and well below the level needed to support the current debt burden. The five-factor DuPont interest burden was 0.991, because non-operating income largely offset financing costs at the pre-tax level; this does not reduce the underlying risk posed by negative EBIT and ¥0.16bn of quarterly interest expense. The tax burden of 0.915 reflects a tax benefit on the pre-tax loss. The Q1 margin structure is not sustainable if maintained through the year, since gross profit of ¥7.45bn was insufficient to cover ¥9.55bn of SG&A. For a pharmaceutical company, the gross-margin profile is favorable, but the earnings case depends on disciplined commercialization and R&D-related expenditure deployment rather than further gross-margin expansion alone.

Growth Assessment

Q1 revenue of ¥9.70bn represented 21.2% progress against the unchanged full-year revenue forecast of ¥45.70bn, modestly below the standard 25% first-quarter progress rate. The full-year operating-profit target is ¥1.10bn, whereas Q1 recorded an operating loss of ¥2.10bn; this requires a ¥3.20bn swing from the Q1 loss to achieve the full-year target. The full-year target for profit attributable to owners is ¥0.20bn, compared with a Q1 loss of ¥1.91bn, also requiring a pronounced recovery during the remaining nine months. Revenue growth and gross-margin expansion provide an encouraging top-line base, but current expense growth undermines conversion of sales into earnings. The maintenance of guidance indicates management expects materially improved revenue conversion, cost control, or timing effects after Q1. The single reported segment is pharmaceuticals, making group earnings directly dependent on execution in the core pharmaceutical business. Industry-specific growth risk remains high because pharmaceutical sales can be affected by product demand volatility, reimbursement and healthcare-pricing revisions, regulatory requirements, competitive therapies, and the timing of product launches or development programs. The key test for the outlook is whether quarterly SG&A growth moderates decisively below revenue growth while the 76.8% gross margin is maintained.

Financial Health

Liquidity is narrowly positive rather than comfortable. The current ratio was 108.9% and the quick ratio was 104.4%, so current assets exceeded current liabilities, but only by working capital of ¥4.39bn. Current liabilities totaled ¥49.36bn, including ¥42.09bn of short-term loans. Short-term debt represented 78.0% of total interest-bearing debt, creating a substantial maturity mismatch and refinancing dependence. Cash and deposits of ¥9.66bn covered only 0.23x of short-term borrowings, which is a clear liquidity-stress indicator. Cash declined ¥4.35bn, or 31.0% year on year, while short-term loans increased to ¥42.09bn. Total interest-bearing debt was ¥53.94bn, equivalent to a debt-to-equity ratio of 1.44x and debt-to-capital of 55.3%. Although D/E remains below the 2.0x high-risk threshold, the combination of negative EBIT, high short-term debt concentration, and low cash coverage elevates financial risk. Interest coverage was negative 13.39x because EBIT was negative, meaning operating earnings currently do not service interest costs. Equity declined to ¥43.63bn from ¥47.36bn, with the Q1 net loss and negative other comprehensive income reducing capital resilience. Property, plant and equipment totaled ¥38.95bn, or 36.6% of assets, and construction in progress was ¥19.26bn, equal to 49.4% of PPE. This large project pipeline ties up capital and raises execution, completion, and future utilization risk. Accounts payable increased 28.3% to ¥0.67bn, though its absolute size remains small relative to the debt structure.

Notable B/S Changes

Cash and deposits: -¥4.35bn (-31.0%) year on year to ¥9.66bn - reduced liquidity headroom is significant given ¥42.09bn of short-term loans and cash/short-term-debt coverage of only 0.23x. Accounts payable: +¥0.15bn (+28.3%) year on year to ¥0.67bn - the percentage increase is notable, although the absolute amount is modest relative to the company’s debt and working-capital requirements. Construction in progress: ¥19.26bn, representing 49.4% of PPE - a very high proportion of fixed assets remains under construction, increasing execution risk and delaying cash returns on capital investment.

Cash Flow Quality

Cash-flow quality cannot be quantified from the reported period because operating cash flow, investing cash flow, financing cash flow, capital expenditure, and free cash flow figures are not provided. Balance-sheet movements nevertheless point to funding pressure: cash and deposits declined by ¥4.35bn year on year while short-term borrowings increased by ¥0.40bn. Accounts receivable increased ¥1.53bn, or 10.8%, to ¥15.69bn. The quality alert indicating days sales outstanding of 148 days highlights slow cash collection relative to sales and raises the risk that accounting revenue is not converting promptly into cash. Inventory-related alerts indicate elevated working-capital intensity, including reported inventory days of 89 days and a broader inventory-duration measure of 993 days associated with production inventories. Raw materials of ¥14.54bn and work in process of ¥7.73bn are substantial capital commitments for a company generating ¥9.70bn of quarterly revenue. The 1,113-day cash conversion cycle alert indicates that cash is tied up for an extended period across receivables and production inventory. These conditions increase reliance on external short-term financing and make improvement in collections, inventory planning, and project completion important for cash preservation.

Dividend Sustainability

The unchanged full-year dividend forecast is ¥20 per share. Against forecast EPS of ¥1.64, the implied dividend payout ratio is approximately 1,220%, which is not covered by forecast earnings. Q1 EPS was negative ¥15.64 and profit attributable to owners was a ¥1.91bn loss, so current-period earnings provide no dividend coverage. Retained earnings remained sizable at ¥28.10bn, but declined from ¥31.23bn in the prior-year quarter. The combination of losses, low cash coverage of short-term debt, and significant construction in progress weakens the financial flexibility available for shareholder distributions. Dividend sustainability therefore depends on the expected second-half earnings recovery, refinancing access, and preservation of cash rather than on Q1 earnings. The stated dividend forecast should be assessed alongside subsequent operating-profit delivery and changes in short-term debt.

Risk Assessment

Business risks include Cost-execution risk: SG&A increased 40.1% year on year, far above 13.2% revenue growth, causing operating margin to deteriorate to negative 21.7%., Pharmaceutical commercialization and regulatory risk: revenue growth must be sustained amid reimbursement changes, competitive therapies, product-demand variability, regulatory compliance requirements, and development-program timing uncertainty., Working-capital risk: receivable days of 148, inventory alerts of 89 days and 993 days, and a 1,113-day cash conversion cycle indicate extended conversion of revenue and production investment into cash., Capital-project execution risk: construction in progress of ¥19.26bn represents 49.4% of PPE, exposing the company to completion delays, cost overruns, and utilization risk..

Financial risks include Debt-service risk: negative EBIT produced negative 13.39x interest coverage, so operating earnings do not currently cover interest expense., Refinancing risk: ¥42.09bn of short-term loans comprise 78.0% of interest-bearing debt and must be rolled over or repaid on a recurring basis., Liquidity risk: cash of ¥9.66bn covers only 0.23x of short-term borrowings, despite current and quick ratios remaining slightly above 1.0x., Capital-erosion risk: total equity fell by ¥3.73bn year on year to ¥43.63bn, while annualized ROE was negative 17.5% and ROIC was negative 8.8%..

Key concerns include The FY2027 operating-profit target of ¥1.10bn requires a substantial reversal from the ¥2.10bn Q1 operating loss., The high gross margin of 76.8% is being overwhelmed by SG&A intensity of 98.5% of revenue., Cash declined 31.0% year on year while the company remains dependent on short-term debt funding., The unchanged ¥20 dividend forecast is not supported by forecast EPS of ¥1.64 or Q1 losses..

Investment Implications

Key takeaways include Revenue and gross profit grew strongly, with gross margin expanding by about 430 basis points to 76.8%., Expense growth was the decisive negative factor: SG&A increased ¥2.74bn year on year and widened the operating loss to ¥2.10bn., The balance sheet is characterized by high short-term funding dependence, with ¥42.09bn of short-term debt versus ¥9.66bn of cash., Large construction in progress and prolonged working-capital metrics increase the importance of cash discipline and operational execution., Achievement of unchanged full-year guidance requires a material improvement in operating profitability after Q1..

Metrics to watch include Quarterly revenue progress versus the ¥45.70bn full-year forecast, Gross margin retention relative to the Q1 level of 76.8%, SG&A growth relative to revenue growth and SG&A-to-sales ratio, Operating-profit recovery versus the ¥1.10bn full-year target, Cash and deposits, short-term loan balance, and refinancing terms, Receivable days, inventory duration, and cash conversion cycle, Construction-in-progress completion and the resulting utilization of productive assets, Dividend coverage relative to earnings and cash preservation.

Regarding relative positioning, JCR Pharma displays a favorable pharmaceutical gross-margin profile, but its current earnings conversion, annualized ROE of negative 17.5%, and short-term-debt dependence are weaker than would be expected for a financially resilient innovator pharmaceutical company. The company’s near-term positioning is therefore determined less by gross-margin potential than by cost control, cash conversion, capital-project execution, and delivery of the heavily back-end-loaded earnings plan.